Table 2 Activity of ALK inhibitors (IC50, nM) on EML4::ALK-transfected Ba/F3 cells, wild-type (WT) or mutant.

From: New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients

IC50 [nM]

Crizotinib

Brigatinib

Ceritinib

Alectinib

Lorlatinib

Zotizalkib

Repotrectinib

WT

90

30

37

19

1.8

7.1

67

E1154K

205

46

129

13

4.6

7.6

64

F1174L

199

57

484

19

5.7

53

227

L1196P

2140

3112

1798

>3000

1854

338

1061

L1198R

230

207

106

59

7.6

7.2

57

T1211I

32

19

23

4.7

0.4

7.0

66

D1232N

45

20

18

8

1.4

7.0

31

C1235R

191

33

110

50

1.8

8.0

42

C1237Y

1230

330

>10,000

>3000

1051

274

488

E1154K + F1174L

159

59

324

40

5.8

31

100

L1196M + G1202Ra

2401

1429

1826

2461

1964

na

na

  1. na not available.
  2. aData from ref. 19.
  3. The data represent the average of three or more independent experiments.
Back to article page